 |
Articles: General Pharma |
Prior Articles
Bristol-Myers Squibb Donation to Benefit Students at The Pennington School and Beyond
Bristol Myers-Squibb Company, 11/04/09
Free full text
ACTEMRA inhibits progression of joint destruction in RA patients by over 80% compared to methotrexate alone
Chugai Pharmaceutical Co., 11/04/09
Free full text
Nabi Biopharmaceuticals Announces Withdrawal of Biotests Indemnification Claim
Nabi Biopharmaceuticals, 11/04/09
Free full text
Enzon Reports Third Quarter Results
Enzon Pharmaceuticals, 11/04/09
Free full text
HIE, Diagnostic Imaging Vendors Align
HealthDataManagement, 11/04/09 Dendreon Completes Submission of Biologics License Application for PROVENGE
Dendreon Coproration, 11/03/09
Free full text
Retigabine Regulatory Update
GlaxoSmithKline, 11/03/09
Free full text
Abbotts XIENCE PRIME and XIENCE V Receive Indications in Europe for Treatment of Patients with Diabetes
Abbott, 11/03/09 Bernhard Hampl, Ph.D. Elected to Serve as Executive Chairman of the Board of Directors of Fresenius Kabi Pharmaceuticals Holding, Inc
American Pharmaceutical Partners, 11/03/09
Free full text
Gilead Sciences Announces Plans for Phase IV Clinical Trial Evaluating First-Line Combination Therapy Versus Monotherapy in Pulmonary Arterial Hypertension
Gilead, 11/03/09
Free full text
ARIADs AP24534 Featured in Cancer Cell Publication as a Potential First-in-Class Pan BCR-ABL Inhibitor
ARIAD Pharmaceuticals, 11/03/09
Free full text
Mayo Clinic Proceedings Publishes Study of NUVIGIL in Patients with Shift Work Disorder
Cephalon, 11/03/09
Free full text
GlaxoSmithKline and Human Genome Sciences announce positive results in second of two phase 3 trials of Benlysta in systemic lupus erythematosus
GlaxoSmithKline, 11/03/09
Free full text
Boehringer Ingelheim announces record productivities for CHO cells using the BI-HEX technology platform
Boehringer Ingelheim, 11/03/09
Free full text
Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) Injection Update
Amylin Pharmaceuticals, 11/03/09
Free full text
Lundbeck starts clinical phase IIa with Lu AA24493 in Friedreich's ataxia in a study also assessing efficacy via biomarkers
Lundbeck, 11/03/09
Free full text
Morphotek, Inc. Announces a Licensing Deal with Centocor Ortho Biotech Inc. for Exclusive Development and Commercialization Rights for a Therapeutic Monoclonal Antibody
Morphotek, 11/03/09
Free full text
NovaRad Adds RIS/PACS Contracts in Kentucky
Imaging Economics, 11/03/09 Getting Devices to Talk to EHRs
HealthDataManagement, 11/03/09 Dell Tries to Make an EHR Splash
HealthDataManagement, 11/03/09
|
|
Receive free subspecialty "5-minute updates" via email
|
|
Indexed Journals: U.S.Pharmacist, FDA Drug Alerts, Pharmiweb
more...
|
250 Available Pages
|
|
